NovoCure (NVCR) reported a Q1 net loss Thursday of $0.31 per diluted share, narrowing from a loss of $0.36 a year earlier.
Analysts polled by FactSet expected a loss of $0.46.
Revenue for the quarter ended March 31 was $155 million, compared with $138.5 million a year earlier.
Analysts surveyed by FactSet expected $146.9 million.
Shares of the company rose more than 6% in premarket activity.